Platelet Aggregation Inhibitors
"Platelet Aggregation Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
Descriptor ID |
D010975
|
MeSH Number(s) |
D27.505.954.502.780
|
Concept/Terms |
Platelet Aggregation Inhibitors- Platelet Aggregation Inhibitors
- Aggregation Inhibitors, Platelet
- Inhibitors, Platelet Aggregation
- Blood Platelet Antiaggregants
- Antiaggregants, Blood Platelet
- Platelet Antiaggregants
- Antiaggregants, Platelet
- Blood Platelet Aggregation Inhibitors
Antiplatelet Agents- Antiplatelet Agents
- Agents, Antiplatelet
- Antiplatelet Drugs
- Drugs, Antiplatelet
Platelet Antagonists- Platelet Antagonists
- Antagonists, Platelet
- Blood Platelet Antagonists
- Antagonists, Blood Platelet
|
Below are MeSH descriptors whose meaning is more general than "Platelet Aggregation Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Platelet Aggregation Inhibitors".
This graph shows the total number of publications written about "Platelet Aggregation Inhibitors" by people in this website by year, and whether "Platelet Aggregation Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1996 | 1 | 0 | 1 |
1998 | 3 | 1 | 4 |
2000 | 1 | 3 | 4 |
2002 | 2 | 1 | 3 |
2003 | 1 | 1 | 2 |
2004 | 1 | 1 | 2 |
2005 | 1 | 1 | 2 |
2006 | 1 | 1 | 2 |
2007 | 4 | 3 | 7 |
2008 | 4 | 1 | 5 |
2009 | 3 | 1 | 4 |
2010 | 3 | 4 | 7 |
2011 | 2 | 2 | 4 |
2012 | 4 | 1 | 5 |
2013 | 1 | 2 | 3 |
2014 | 5 | 5 | 10 |
2015 | 1 | 2 | 3 |
2016 | 3 | 0 | 3 |
2017 | 1 | 0 | 1 |
2018 | 3 | 3 | 6 |
2019 | 1 | 1 | 2 |
2020 | 3 | 1 | 4 |
2021 | 9 | 3 | 12 |
2022 | 2 | 4 | 6 |
2023 | 2 | 7 | 9 |
2024 | 0 | 4 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Platelet Aggregation Inhibitors" by people in Profiles.
-
Age and Aspirin Dosing in Secondary Prevention of Atherosclerotic Cardiovascular Disease. J Am Heart Assoc. 2024 Feb 20; 13(4):e026921.
-
Antithrombotic Treatment for Stroke Prevention in Cervical Artery Dissection: The STOP-CAD Study. Stroke. 2024 Apr; 55(4):908-918.
-
Editors' Note: IV Thrombolysis vs Early Dual Antiplatelet Therapy in Patients With Mild Noncardioembolic Ischemic Stroke. Neurology. 2024 Mar 12; 102(5):e209236.
-
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease and Diabetes Mellitus: A Subgroup Analysis of the ADAPTABLE Trial. Diabetes Care. 2024 Jan 01; 47(1):81-88.
-
Vulnerable and Stabilized States After Cerebral Ischemic Events: Implications of Kinetic Modeling in the SOCRATES, POINT, and THALES Trials. Neurology. 2023 Nov 27; 101(22):e2205-e2214.
-
Effectiveness and Safety of Enteric-Coated vs Uncoated Aspirin in Patients With Cardiovascular Disease: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial. JAMA Cardiol. 2023 11 01; 8(11):1061-1069.
-
Low dose intravenous cangrelor versus glycoprotein IIb/IIIa inhibitors in endovascular treatment of tandem lesions. J Stroke Cerebrovasc Dis. 2023 Dec; 32(12):107438.
-
Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients Treated With P2Y12 Inhibitors. J Am Heart Assoc. 2023 10 17; 12(20):e030385.
-
Safety Outcomes of Mechanical Thrombectomy Versus Combined Thrombectomy and Intravenous Thrombolysis in Tandem Lesions. Stroke. 2023 10; 54(10):2522-2533.
-
Safety and efficacy of tirofiban in the management of stroke: A systematic review and meta-analysis of randomized controlled trials. Clin Neurol Neurosurg. 2023 09; 232:107867.